Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.
CSPC Pharmaceutical Group Limited has announced that its Cobamamide Capsules have received drug registration approval from the National Medical Products Administration of China. This approval enhances the company’s product portfolio in the therapeutic areas of hematology and neurology, potentially strengthening its market position and offering new treatment options for various types of anemia and nerve-related conditions.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.21 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry. The company focuses on developing and manufacturing a range of pharmaceutical products, with a particular emphasis on hematology and neurology.
Average Trading Volume: 175,570,876
Technical Sentiment Signal: Buy
Current Market Cap: HK$90.04B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.